The incidence and prevalence of IgA nephropathy in Europe.

"CONFLICT OF INTEREST STATEMENT C.J.W. has served as an epidemiologic consultant to Otsuka/Visterra, Janssen Pharmaceuticals, and Healx. R.C. has been a consultant or advisory board member for Amgen, Argenx, Calliditas Therapeutics, Menarini, Novartis, Otsuka/Visterra, Purespring, Reata Pharmaceuticals, Stadapharm, and Travere Therapeutics. F.S. has received consultancy fees from Alexion, Otsuka, and Novartis. M.M.W. declares no conflict of interest. M.M. is a full-time employee of Visterra, Inc. M.J.S. was a full-time employee of Visterra, Inc. at the time of this work, and is currently a full-time employee of Otsuka Pharmaceutical Development & Commercialization Inc."

"FUNDING This work was supported by Visterra, Inc. (Waltham, MA, USA), a member of the Otsuka family of companies. Authors affiliated with the sponsors were involved in the design of the study, the analysis and interpretation of data, the writing and reviewing of this article, and the decision to submit the article for publication."